Helen Sabzevari
CIK 1724195 · President and CEO · last filed 2026-08-25
Helen Sabzevari is a President and CEO who has filed 55 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for PGEN, was dated Aug 25, 2026. Across all open-market trades the lifetime net is −$6.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $24.0M across reported positions. 52 SEC filings were submitted jointly with INTREXON CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PGEN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
GERMANTOWN, MD 20876
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PGEN | President and CEO | 3,779,521 | $6.36 | $24.02M | -$6.53M | 37 | 2026-08-25 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | — | $2.65 | — | $0 | 3 | 2023-06-13 |
| PRECIGEN, INC. (XON) Delisted | President and CEO | 104,734 | — | — | -$366.3K | 13 | 2020-01-07 |
Recent Filings
55 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-25 | PGEN | Mixed | +10,649 | -$73.3K | EDGAR |
| 2026-07-01 | PGEN | Mixed | — | -$1.23M | EDGAR |
| 2026-06-29 | PGEN | Notice (144) | −346,836 | -$2.04M | EDGAR |
| 2026-06-01 | PGEN | Sell (S) | −119,250 | -$519.9K | EDGAR |
| 2026-05-27 | PGEN | Exer (M) | +250,000 | $0 | EDGAR |
| 2026-04-22 | PGEN | Grant (A) | — | $0 | EDGAR |
| 2026-03-20 | PGEN | Mixed | +321,100 | $0 | EDGAR |
| 2025-09-16 | PGEN | Grant (A) | — | $0 | EDGAR |
| 2025-06-27 | PGEN | Grant (A) | — | $0 | EDGAR |
| 2025-05-27 | PGEN | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.